Maximal T Cell–Mediated Antitumor Responses Rely upon CCR5 Expression in Both CD4+ and CD8+ T Cells
Authors:
- Alicia González-MartínAGAlicia González-Martín
- Lucio GómezLGLucio Gómez
- Joseph LustgartenJLJoseph Lustgarten
- Emilia MiraEMEmilia Mira
- Santos MañesSantos Mañes
Open Access
- 11 August 2011
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 71 (16) , 5455-5466
Abstract
Mutations of the von Hippel-Lindau (VHL) gene are frequent in clear cell renal cell carcinomas (ccRCC). Nonsense and frameshift mutations abrogate the function of the VHL protein (pVHL), whereas missense mutations can have different effects. To identify those missense mutations with functional consequences, we sequenced VHL in 256 sporadic ccRCC and identified 187 different VHL mutations of which 65 were missense mutations. Location and destabilizing effects of VHL missense mutations were determined in silico. The majority of the thermodynamically destabilizing missense mutations were located in exon 1 in the core of pVHL, whereas protein surface mutations in exon 3 affected the interaction domains of elongin B and C. Their impact on pVHL's functionality was further investigated in vitro by stably reintroducing VHL missense mutations into a VHL null cell line and by monitoring the green fluorescent protein (GFP) signals after the transfection of a hypoxia inducible factor (HIF)α-GFP expression vector. pVHL's functionality ranged from no effect to complete HIF stabilization. Interestingly, Asn78Ser, Asp121Tyr, and Val130Phe selectively influenced HIF1α and HIF2α degradation. In summary, we obtained three different groups of missense mutations: one with severe destabilization of pVHL; a second without destabilizing effects on pVHL but relevance for the interaction with HIFα, elongin B, and elongin C; and a third with pVHL functions comparable with wild type. We therefore conclude that the specific impact of missense mutations may help to distinguish between driver and passenger mutations and may explain responses of ccRCC patients to HIF-targeted therapies. Cancer Res; 71(16); 5500–11. ©2011 AACR.Keywords
All Related Versions
This publication has 88 references indexed in Scilit:
- CD4+ T Cells Elicit Host Immune Responses to MHC Class II− Ovarian Cancer through CCL5 Secretion and CD40-Mediated Licensing of Dendritic CellsThe Journal of Immunology, 2010
- CCR5 Deficiency Is a Risk Factor for Early Clinical Manifestations of West Nile Virus Infection but not for Viral TransmissionThe Journal of Infectious Diseases, 2010
- Opposing Effects of Toll-like Receptor (TLR3) Signaling in Tumors Can Be Therapeutically Uncoupled to Optimize the Anticancer Efficacy of TLR3 LigandsCancer Research, 2010
- Successful immunotherapy with IL-2/anti-CD40 induces the chemokine-mediated mitigation of an immunosuppressive tumor microenvironmentProceedings of the National Academy of Sciences, 2009
- Tunable Chemokine Production by Antigen Presenting Dendritic Cells in Response to Changes in Regulatory T Cell Frequency in Mouse Reactive Lymph NodesPLOS ONE, 2009
- CXCR4–CCR5: A couple modulating T cell functionsProceedings of the National Academy of Sciences, 2008
- Cancer-related inflammationNature, 2008
- Dynamic imaging of chemokine-dependent CD8+ T cell help for CD8+ T cell responsesNature Immunology, 2007
- In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumorJournal of Experimental Medicine, 2007
- Alloantigen-enhanced accumulation of CCR5+‘effector’ regulatory T cells in the gravid uterusProceedings of the National Academy of Sciences, 2007